809 related articles for article (PubMed ID: 28189754)
21. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
[TBL] [Abstract][Full Text] [Related]
22. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
[TBL] [Abstract][Full Text] [Related]
23. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
[TBL] [Abstract][Full Text] [Related]
24. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Feld JJ; Ramji A; Shafran SD; Willems B; Marotta P; Huchet E; Vachon ML; Svarovskaia ES; Huang KC; Hyland RH; Yun C; Massetto B; Brainard DM; McHutchison JG; Tam E; Bailey R; Cooper C; Yoshida EM; Greenbloom S; Elkhashab M; Borgia S; Swain MG
Clin Infect Dis; 2017 Jul; 65(1):13-19. PubMed ID: 28535298
[TBL] [Abstract][Full Text] [Related]
25. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
Babatin MA; AlGhamdi AS; Assiri AM; AlBiladi H; AlOthmani HS; Mogharbel MH; Mahallawi W; Asselah T; Sanai FM
Saudi J Gastroenterol; 2019; 25(1):55-60. PubMed ID: 30117490
[TBL] [Abstract][Full Text] [Related]
26. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A
J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
29. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
31. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Osinusi A; Kohli A; Marti MM; Nelson A; Zhang X; Meissner EG; Silk R; Townsend K; Pang PS; Subramanian GM; McHutchison JG; Fauci AS; Masur H; Kottilil S
Ann Intern Med; 2014 Nov; 161(9):634-8. PubMed ID: 25364884
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Lashen SA; Shamseya MM; Madkour MA; Aboufarrag GA
Liver Int; 2019 May; 39(5):835-843. PubMed ID: 30549417
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Murray KF; Balistreri WF; Bansal S; Whitworth S; Evans HM; Gonzalez-Peralta RP; Wen J; Massetto B; Kersey K; Shao J; Garrison KL; Parhy B; Brainard DM; Arnon R; Gillis LA; Jonas MM; Lin CH; Narkewicz MR; Schwarz K; Rosenthal P
Hepatology; 2018 Dec; 68(6):2158-2166. PubMed ID: 30070726
[TBL] [Abstract][Full Text] [Related]
35. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Smith MA; Chan J; Mohammad RA
Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
[TBL] [Abstract][Full Text] [Related]
36. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
37. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
[TBL] [Abstract][Full Text] [Related]
39. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
[TBL] [Abstract][Full Text] [Related]
40. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Quintero J; Juampérez J; Julio E; Cabello V; Mercadal-Hally M; Soler-Palacín P; Segarra Ó; Rodrigo C
An Pediatr (Engl Ed); 2019 Mar; 90(3):141-147. PubMed ID: 30126773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
